CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
15.4 CAD
-0.14 (-0.9%)
We assign a fundamental rating of 7 out of 10 to CPH. CPH was compared to 35 industry peers in the Pharmaceuticals industry. CPH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPH is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make CPH suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year CPH was profitable.
- CPH had a positive operating cash flow in the past year.
- CPH had positive earnings in each of the past 5 years.
- CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 11.77%, CPH belongs to the top of the industry, outperforming 91.43% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 15.23%, CPH belongs to the top of the industry, outperforming 88.57% of the companies in the same industry.
- The Return On Invested Capital of CPH (7.23%) is better than 88.57% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.45%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
- With an excellent Profit Margin value of 34.68%, CPH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Profit Margin of CPH has grown nicely.
- CPH has a Operating Margin of 25.51%. This is amongst the best in the industry. CPH outperforms 85.71% of its industry peers.
- In the last couple of years the Operating Margin of CPH has declined.
- Looking at the Gross Margin, with a value of 74.32%, CPH belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
- In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CPH is creating some value.
- CPH has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for CPH has been reduced compared to 5 years ago.
- Compared to 1 year ago, CPH has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 6.58 indicates that CPH is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 6.58, CPH belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
- CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.45, CPH belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
- A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
- CPH's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CPH outperforms 68.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.58 |
ROIC/WACC0.87
WACC8.31%
2.3 Liquidity
- CPH has a Current Ratio of 1.30. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
- CPH has a Current ratio of 1.30. This is in the lower half of the industry: CPH underperforms 62.86% of its industry peers.
- A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
- With a Quick ratio value of 0.98, CPH perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
- CPH does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
- CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
- CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
- CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.17%.
- The Revenue has been growing by 8.25% on average over the past years. This is quite good.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
- CPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.66% yearly.
- CPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.91% yearly.
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- CPH is valuated correctly with a Price/Earnings ratio of 16.74.
- Based on the Price/Earnings ratio, CPH is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
- CPH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.47.
- CPH is valuated rather expensively with a Price/Forward Earnings ratio of 17.83.
- CPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CPH is cheaper than 71.43% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.26, CPH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.74 | ||
| Fwd PE | 17.83 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as CPH.
- Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than 77.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.39 | ||
| EV/EBITDA | 14.64 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of CPH may justify a higher PE ratio.
- A more expensive valuation may be justified as CPH's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)0.33
PEG (5Y)1.29
EPS Next 2Y16.2%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
- No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (1/16/2026, 7:00:00 PM)
15.4
-0.14 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-16 2026-03-16
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap390.70M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target19.58 (27.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)2.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.59%
Revenue NQ rev (1m)0.79%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.74 | ||
| Fwd PE | 17.83 | ||
| P/S | 5.61 | ||
| P/FCF | 9.39 | ||
| P/OCF | 9.37 | ||
| P/B | 2.47 | ||
| P/tB | 12.3 | ||
| EV/EBITDA | 14.64 |
EPS(TTM)0.92
EY5.97%
EPS(NY)0.86
Fwd EY5.61%
FCF(TTM)1.64
FCFY10.65%
OCF(TTM)1.64
OCFY10.68%
SpS2.74
BVpS6.24
TBVpS1.25
PEG (NY)0.33
PEG (5Y)1.29
Graham Number11.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.58 |
F-Score7
WACC8.31%
ROIC/WACC0.87
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year136.94%
EBIT Next 3Y50.11%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.74 and the Price/Book (PB) ratio is 2.47.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.